Figures
- FIGURE 1
Map of included Mycobacterium simiae complex isolates (public and from this study) and their respective sampling origin (environmental, human, zoonotic).
- FIGURE 2
a) Phylogenetic tree of publicly available sequences and isolates from included patients attending the University Hospital Frankfurt from 2006 to 2020 and b) heat map of average nucleotide identities of included isolates. NA: not applicable; P: patient; ANI: average nucleotide identity.
- FIGURE 3
a) Timeline of patients’ visits to the hospital (grey dots depict singular visits or dates, black bars represent in-hospital stays) and b) heatmap of patient interaction. P: patient.
Tables
- TABLE 1
General characteristics of patients with isolation of Mycobacterium simiae
Sex Male 5/7 Female 2/7 Disposition CF 3/7 Non-CF 4/7 HIV 1/7 Malignoma 2/7 SLD 2/7 Clinical manifestation Isolated pulmonary 6/7 Isolated extrapulmonary 0/7 Disseminated 1/7 ATS criteria 2/6 Pulmonary symptoms and radiology 2/6 Exclusion other diagnosis 2/6 Two culture-positive sputa 3/6 Positive culture in BALF 3/6 Biopsy and culture 1/6 NTM therapy 3/7 Macrolide 3/3 Ethambutol 1/3 Rifamycin 1/3 Fluoroquinolone 3/3 Clofazimin 1/3 Cotrimoxazol 2/3 Linezolid 1/3 Deceased 0/7 Culture conversion 5/7 Other NTM isolated during the observation period M. abscessus 2/7 M. chimaera 1/7 M. intracellulare 1/7 M. chelonae 1/7 CF: cystic fibrosis; SLD: structural lung disease; BALF: bronchoalveolar lavage fluid; NTM: non-tuberculous mycobacterium.
- TABLE 2
Clinical course of patients with isolation of Mycobacterium simiae
Patient Sex Age years Disposition Clinical manifestation Pulmonary radiology ATS criteria fulfilled Other NTM species NTM therapy Outcome P1 m 37 CF Pulmonary Bronchiectasis, nodular changes y M. chimaera Clarithromycin, moxifloxacin, clofazimine, cotrimoxazole Culture conversion, alive P2 m 70 Malignoma Pulmonary Bronchiectasis, malignoma n NA n Culture conversion, alive P3 m 78 Malignoma Pulmonary Infiltration, pleural effusion n NA n Alive P4 m 63 SLD (emphysema, bronchiectasis) Pulmonary Bronchiectasis, carnificating pneumonia n NA n Alive P5 f 36 CF Pulmonary Bronchiectasis y M. abscessus, M. intracellulare, M. chelonae Clarithromycin, levofloxacin, linezolid Culture conversion, alive P6 m 36 CF Pulmonary Bronchiectasis, infiltration n M. abscessus n Culture conversion, alive P7 f 41 HIV CDC Stadium C3 Disseminated Slight emphysema NA NA Clarithromycin/azithromycin, ethambutol, rifabutin, levofloxacin, cotrimoxazole Culture conversion, alive NTM: non-tuberculous mycobacterium; P: patient; CF: cystic fibrosis; SLD: structural lung disease; CDC: Centers for Disease Control and Prevention; NA: not applicable; m: male; f: female; y: yes; n: no.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material 00773-2023.SUPPLEMENT
